Glucuronidation: driving factors and their impact on glucuronide disposition
Total Time: 45-60 minutes Frequency: Typically 1-2 sessions weekly initially, then maintenance every 4-6 weeks
This convergent, multi-model, multi-group signal is the most reproducible neuro-specific finding for the compound though it remains preclinical, with no human neurological trials
However, due to limited study and potential adverse effects, its use for this purpose is neither generally accepted nor advised
Most of the evidence for using them together comes from smaller clinical observations or the professional judgment of specialists who treat metabolic health
However, retatrutide remains an investigational medicinal product and, as of mid-2025, has not been approved for clinical use in the United Kingdom or elsewhere